Clinical Trials Logo
  1. Home
  2. Lung Squamous Cell Carcinoma
  3. NCT05782764

A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom

Lung Squamous Cell Carcinoma Clinical Trial

Official title:
A Single-arm, Exploratory Clinical Study of 3-day Continuous Intravenous Pump of Endostatin (Endostar) Combined With Chemotherapy and Immune Checkpoint Inhibitor in the Treatment of Advanced Lung Squamous Cell Carcinom

Clinical Trial Summary

To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).

Clinical Trial Description

This study is a prospective, single-arm, single-center phase II study to evaluate the efficacy and safety of immune checkpoint inhibitors in combination with chemotherapy and recombinant human endostatin in patients with advanced (stage IIIB-IV) squamous non-small cell lung cancer. Patients with locally advanced stage ⅢB/ⅢC, metastatic or recurrent stage IV squamous NSCLC who were not operable and could not receive radical concurrent chemoradiotherapy were selected after signing informed consent. Eligible subjects who met the inclusion criteria were screened for immune checkpoint inhibitor combined with chemotherapy and recombinant human endostatin. After cycles 4 to 6, maintenance therapy with an immune checkpoint inhibitor and endostatin was administered until disease progression, unacceptable toxicity, withdrawal of consent, initiation of additional antineoplastic therapy, death, or other protocol-specified discontinuation of treatment, whichever occurred first. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05782764
Study type Interventional
Source Xuzhou Medical University
Contact Min Liu
Phone +86 66696891
Email lmin89@163.com
Status Recruiting
Phase Phase 4
Start date June 1, 2023
Completion date May 30, 2025
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT04267913 - Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) Phase 2
Not yet recruiting NCT03725423 - Apatinib for Advanced Lung Squmamous Carcinoma Phase 4
Recruiting NCT06255197 - Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Recruiting NCT04132102 - To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation Phase 4
Active, not recruiting NCT04152018 - Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Phase 1
Recruiting NCT05778253 - The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
Recruiting NCT02876978 - Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma Phase 1
Completed NCT01807546 - Oral Rigosertib for Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT01386385 - Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Phase 1/Phase 2
Active, not recruiting NCT00334815 - Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Phase 2
Recruiting NCT05010330 - Identify Prognostic Biomarkers of Lung Cancer
Recruiting NCT06436040 - Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
Recruiting NCT05024266 - Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma Phase 2
Recruiting NCT04802876 - Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Phase 2